CHRS Stock Forecast: Coherus Oncology, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Coherus Oncology, Inc. is $7.5. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 38 of 100 as at 21 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Coherus Oncology, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (95): Sales and profits are climbing, and climbing faster than before.
Issuance (12): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
CHRS stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on CHRS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 10 Nov 2026 | Guggenheim | Maintains | Buy | $10 → $8.00 |
| 29 Oct 2026 | HC Wainwright & Co. | Assumes | Buy | $7.00 |
| 7 Aug 2026 | Guggenheim | Maintains | Buy | $12 → $10 |
| 11 May 2026 | Guggenheim | Initiates | Buy | — |
| 22 Jan 2026 | Oppenheimer | Initiates | Outperform | — |
| 4 Sept 2025 | Maxim Group | Upgrade | Buy | — |
| 29 Apr 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 24 Apr 2025 | UBS | Maintains | Neutral | — |
| 11 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 23 Jan 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 22 Jan 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 5 Dec 2024 | Baird | Maintains | Outperform | — |
| 4 Dec 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 8 Nov 2024 | Baird | Maintains | Outperform | — |
| 7 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 16 Sept 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 16 Aug 2024 | UBS | Downgrade | Neutral | — |
| 5 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 1 July 2024 | Baird | Maintains | Outperform | — |
| 24 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for CHRS.
This page is one stock. Monday covers all of them.
CHRS appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
CHRS vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Coherus Oncology, Inc. returned −66.4% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
CHRS analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 1.1×
- Price / book
- 2.3×
- EV / EBITDA
- —
Cheaper than 64% of US stocks
Cheaper than 40% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- 70.4%
- Operating margin
- —
- Net margin
- —
Higher than 83% of US stocks
- Return on equity
- −275.2%
- Return on assets
- −26.4%
- Dividend yield
- —
Higher than 5% of US stocks
Higher than 16% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Coherus Oncology, Inc. has a market value of $57.2M and an enterprise value of $43.1M.
Revenue in the twelve months to 30 June 2026: $50.9M. The latest quarter grew 39.5% year on year.
Net income over the same four quarters: −$132.1M, a −259.4% net margin.
Diluted earnings per share, trailing twelve months: −$1.03.
Free cash flow in the twelve months to 30 June 2026: −$186.0M.
Coherus Oncology, Inc. employs 145 people — $351K of revenue per employee.
Data provided by Twelve Data
CHRS and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at CHRS’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Coherus Oncology, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about CHRS
What is the CHRS stock price forecast for 2026-2027?
The median 12-month analyst price target for Coherus Oncology, Inc. is $7.5, with estimates ranging from $4 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is CHRS stock a buy right now?
Of the 6 analysts covering Coherus Oncology, Inc., 5 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Coherus Oncology, Inc. 38 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank CHRS?
As at 21 Nov 2026, Coherus Oncology, Inc. ranks 38 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (95 of 100).
Will CHRS stock go up?
No one can know that. What the data says: the median 12-month target from 6 analysts is $7.5, and Ticker Nerd's factor model ranks Coherus Oncology, Inc. 38 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the CHRS stock forecast for 2030?
No analyst covering Coherus Oncology, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CHRS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $10 over the next 12 months.
How has CHRS stock performed over the past year?
Coherus Oncology, Inc. returned -66.4% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Coherus Oncology, Inc. do?
Coherus Oncology, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative immuno-oncology therapies for cancer. The company’s current portfolio centers on LOQTORZI, an approved PD-1 inhibitor used in oncology treatment, alongside additional clinical-stage candidates designed to address several solid tumors and tumor types.
About Coherus Oncology, Inc.
Coherus Oncology, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative immuno-oncology therapies for cancer. The company’s current portfolio centers on LOQTORZI, an approved PD-1 inhibitor used in oncology treatment, alongside additional clinical-stage candidates designed to address several solid tumors and tumor types. Coherus Oncology works across research, regulatory development, manufacturing, and commercialization, with an emphasis on combination therapies that may expand the use of its cancer medicines. Its business is concentrated on oncology therapeutics, reflecting a focused role in the cancer drug market and a strategy built around antibody-based and immune-based treatments. Based in Redwood City, California, Coherus Oncology serves as a specialized player in the U.S. biopharmaceutical sector, with its commercial activities and pipeline development aimed at improving treatment options in modern oncology.
CEO Mr. Dennis M. Lanfear · 145 employees · United States · https://www.coherus.com